While valuations across the pharmaceutical industry have soared this year -- with shares of diversified giants like Merck (MRK 1.10%) and Pfizer up significantly -- Bristol-Myers Squibb (BMY 1.31%) in particular has been on a tear recently. In the last 12 months, its shares are up a whopping 40%. However, despite all of the promising drugs that the company is developing in clinical trials, is there any upside left in this stock today? In the following video, analysts David Williamson and Max Macaluso discuss three reasons to consider selling Bristol-Myers.
3 Reasons to Sell Bristol-Myers Squibb
By Max Macaluso and Dave Williamson – Sep 25, 2013 at 6:30PM
NYSE: BMY
Bristol Myers Squibb
Market Cap
$87B
Today's Change
(-1.31%) $0.57
Current Price
$42.82
Price as of October 28, 2025 at 4:00 PM ET
Are there any reasons to sell one of the best performing pharmaceutical stocks of the year?
About the Author
Max is the Technology, Biopharma & Health Care Bureau Chief at Fool.com. Prior to joining the Fool, he completed a PhD in chemistry at the University of Cambridge and an MBA at the College des Ingenieurs.
Follow @TMFMassimo